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Introduction {#cam41406-sec-0001}
============

Disseminated ovarian cancer is an incurable disease [1](#cam41406-bib-0001){ref-type="ref"}. However, if diagnosed in its early stage, resection and adjuvant chemotherapy can reduce the probability of the tumor to relapse and spread [2](#cam41406-bib-0002){ref-type="ref"}. Unfortunately, some patients with early stage ovarian cancer (mainly stage 1 and 2) are still at high risk of relapse, even after being treated with adequate surgical and adjuvant chemotherapy [2](#cam41406-bib-0002){ref-type="ref"}. In this context, the identification of patients who have high risk of recurrence is desirable as it can influence adjuvant treatment and guide future drug development.

Similar to other cancers, in ovarian cancer, different molecular mechanisms are responsible for cancer initiation and progression. Uncontrolled proliferation, migration, evasion from immunological regulation, or the capacity to generate new vessels are, among others, oncogenic hallmarks of ovarian cancer [3](#cam41406-bib-0003){ref-type="ref"}. Of note, agents that mitigate these functions, such as antimitotic chemotherapies, DNA damaging agents or anti‐angiogenic compounds, have reached the clinical practice [3](#cam41406-bib-0003){ref-type="ref"}, [4](#cam41406-bib-0004){ref-type="ref"}. Among agents that target classical deregulated functions such as cell division or proliferation, novel vulnerabilities with potential for therapeutic capacity are under evaluation, including protein modifications or epigenetic events. New drugs targeting the proteasome, ubiquitination, or bromodomains are currently under evaluation in several solid tumors [5](#cam41406-bib-0005){ref-type="ref"}.

In this context, it will be desirable to identify biological functions that are characteristically deregulated in ovarian cancer at a transcriptomic and proteomic level. Genomic signatures and protein--protein interacting networks could be used to select patients with higher risk of relapse in the long term. Furthermore, molecular elements involved in these biological functions could be potentially druggable, opening the door to evaluate new compounds against these alterations in the clinical setting. With this approach in mind, we have described genes and gene signatures associated with mitosis that predicted poor outcome specifically in patients with early stage ovarian tumors [6](#cam41406-bib-0006){ref-type="ref"}. However, we envision that an analysis based of functional genomics and protein--protein interactions could provide more robust prediction outcome in ovarian cancers, and a more general overview of the biological characteristics of this disease.

In this project using an *in silico* approach using public transcriptomic data, we identified deregulated functions in early stage ovarian cancer that were associated with worse outcome. Expression of some of these signatures identified patients at a higher risk. A protein--protein interaction analysis revealed hubs of proteins with oncogenic implications that could be inhibited pharmacologically. Of note, a relevant finding was the identification of the histone‐lysine N‐methyltransferase EZH2, and the ubiquitin‐conjugating enzyme E2C as key upregulated interacting proteins. In addition, these proteins were amplified in 10% and 6% of the ovarian tumors. The data presented opens the door to the further assessment of these signatures in clinical studies, and for the evaluation of novel therapies against the mentioned proteins or pathways.

Material and Methods {#cam41406-sec-0002}
====================

Transcriptomic and gene expression analyses {#cam41406-sec-0003}
-------------------------------------------

To identify differences at a transcriptomic level, we used a public dataset (GEO DataSet accession number: GSE14407) of mRNA levels from twelve isolated ovarian epithelial cell lines and twelve isolated serous ovarian cancer epithelial (CEPI) cells. Affymetrix CEL files were downloaded and analyzed with Affymetrix Transcriptome Analysis Console 3.0. Differential gene expression profile for both groups was performed using a minimum fourfold change. Oncomine^™^ Platform was used to confirm the GEO DataSet findings (<https://www.oncomine.org/resource/login.html>).

Evaluation of clinical outcome {#cam41406-sec-0004}
------------------------------

The publicly available Kaplan--Meier (KM) Plotter Online Tool (<http://kmplot.com/analysis/>) was used to evaluate the relationship between gene expression levels and patient\'s clinical outcome in early stage ovarian cancer (stage I and II). Only genes significantly associated with detrimental outcome (Hazard Ratio ≥1 and *P*‐value ≤0.05) were used for subsequent analysis (*n *= 131). This tool was also used to determine progression‐free survival (PFS) and overall survival (OS) in functional combined analyses. All the analyses were performed independently by two authors (SMC and MLR) and reviewed by a third author (EMGM) (Accession date January 8th 2018). No discrepancies were observed.

Protein--protein interactions maps and functional evaluation {#cam41406-sec-0005}
------------------------------------------------------------

Using the String Online Tool (<http://www.string-db.org>), we constructed the interactome. The PPI map was based on the list of genes associated with poor PFS. Proteins showing less than two interactions were not considered. Subsequently, we performed a functional screening using Ensembl (<http://www.ensembl.org>), and Gene Ontology (GO) by biological function.

Selection of potential drug candidates {#cam41406-sec-0006}
--------------------------------------

We used information from Selleckchem (<http://www.selleckchem.com>) and Genecards (<http://www.genecards.org>) to select potentially druggable genes. Then, as described above, we used the STRING tool to build the druggable ovarian cancer interactome. Based on interacting groups, we divided the PPI map in three functional clusters: cell cycle (*n *= 19), DNA damage (*n *= 4), and angiogenesis (*n *= 3). PPI hubs proteins were determined as those with a higher number of interactions than the average (Edges ≥17.2).

Identification of molecular alterations {#cam41406-sec-0007}
---------------------------------------

We used data contained at cBioportal (<http://www.cbioportal.org>; TCGA Ovarian Serous Cystadenocarcinoma, *n *= 603) to identify potential copy number alterations (amplification or deletion), and the presence of mutations in the identified genes.

Results {#cam41406-sec-0008}
=======

Selection of deregulated genes and functional analyses {#cam41406-sec-0009}
------------------------------------------------------

To identify deregulated functions in ovarian cancer cells, we used public transcriptomic data (GSE14407), to compare isolated serous ovarian cancer epithelial (CEPI) cells with isolated ovarian epithelial cell lines. Using a minimum fold change of four, we identified 2925 genes of which 131 were associated with poor clinical outcome (Fig. [1](#cam41406-fig-0001){ref-type="fig"}A and Table [1](#cam41406-tbl-0001){ref-type="table-wrap"}). The upregulation of the genes was confirmed using data from human samples contained at Oncomine (Table [1](#cam41406-tbl-0001){ref-type="table-wrap"}). Protein--protein interaction network showed 130 nodes and a cluster coefficient of 0.62 (Fig. [S1](#cam41406-sup-0001){ref-type="supplementary-material"}).

![Transcriptomic analyses comparing isolated serous ovarian cancer epithelial (CEPI) cells with isolated ovarian epithelial cells. (A) Identification of deregulated genes (fold change ≥4) which are associated with bad prognosis in CEPI. (B) Functional enrichment analyses identify cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular stimuli and transcription regulation, as the most altered functions in CEPI.](CAM4-7-1896-g001){#cam41406-fig-0001}

###### 

List of deregulated genes associated with bad prognosis

  Probe ID        Transcript ID   Gene symbol   AFFYMETRIX   ONCOMINE   KMPLOTTER                                  
  --------------- --------------- ------------- ------------ ---------- ----------- ---------- ------------------- --------
  211767_at       g13543688       GINS4         4.01         0.002866   2.404       1.11E‐05   2.87 (1.54--5.35)   0.0005
  228729_at       Hs.23960.0      CCNB1         4.03         8.24E‐07   6.152       5.33E‐06   2.85 (1.3--6.22)    0.0062
  1569241_a\_at   Hs2.149839.1    ZNF93         4.06         0.004685   2.296       6.40E‐06   2.41 (1.14--5.08)   0.0176
  205869_at       g4506144        PRSS1         4.06         0.000394   2.008       2.12E‐07   1.91 (1.06--3.45)   0.0296
  213100_at       Hs.13350.0      UNC5B         4.07         0.000451   1.351       0.006      1.82 (1.01--3.3)    0.0432
  216615_s\_at    Hs.2142.1       HTR3A         4.11         0.001305   3.505       4.76E‐16   2.23 (1.19--4.15)   0.0098
  40020_at        4858618_RC      CELSR3        4.13         9.48E‐08   1.502       7.89E‐07   3.86 (1.98--7.54)   0
  219306_at       g9910265        KIF15         4.17         0.000147   3.696       2.29E‐08   2.88 (1.54--5.38)   0.0005
  209342_s\_at    g4185274        IKBKB         4.17         0.007424   1.31        2.12E‐04   2.44 (1.31--4.56)   0.0038
  213759_at       Hs.111554.1     ARL4C         4.21         0.008012   3.624       8.81E‐06   1.89 (1.06--3.39)   0.0289
  206134_at       g7657318        ADAMDEC1      4.21         0.003324   1.87        0.012      1.88 (1.04--3.39)   0.0337
  219787_s\_at    g8922431        ECT2          4.23         0.000033   10.209      2.81E‐08   2.62 (1.42--4.83)   0.0014
  210559_s\_at    g3126638        CDK1          4.23         0.000803   7.317       4.85E‐07   1.8 (1.01--3.23)    0.0447
  204444_at       g13699823       KIF11         4.25         0.000272   5.467       7.52E‐07   2.73 (1.48--5.03)   0.0008
  209053_s\_at    Hs.110457.3     WHSC1         4.25         0.000004   3.805       3.67E‐10   3.03 (1.57--5.84)   0.0005
  209198_s\_at    g13279139       SYT11         4.27         0.000005   2.974       1.43E‐07   3.4 (1.81--6.39)    0.0001
  207156_at       g10800131       HIST1H2AG     4.3          0.006192   1.554       5.81E‐06   1.96 (1.1--3.5)     0.0201
  205544_s\_at    g4503026        CR2           4.34         0.027892   1.428       6.37E‐06   3.37 (1.74--6.53)   0.0001
  203046_s\_at    g4507506        TIMELESS      4.36         4.84E‐07   3.434       2.30E‐09   1.86 (1.03--3.37)   0.0365
  202870_s\_at    g4557436        CDC20         4.41         0.000004   11.259      2.44E‐06   3.87 (2.01--7.46)   0
  202860_at       g7662151        DENND4B       4.43         0.000019   1.563       3.19E‐04   3.3 (1.71--6.37)    0.0002
  214933_at       Hs.96253.2      CACNA1A       4.45         0.000001   2.563       1.47E‐05   2.6 (1.39--4.85)    0.0018
  210587_at       g13477368       INHBE         4.47         0.042977   1.32        7.38E‐05   2.22 (1.2--4.09)    0.0089
  214005_at       Hs.77719.1      GGCX          4.5          2.02E‐08   1.837       2.04E‐04   2.45 (1.35--4.46)   0.0025
  205660_at       g11321576       OASL          4.53         0.006553   2.449       9.95E‐05   2.06 (1.13--3.78)   0.0165
  219454_at       g13124887       EGFL6         4.54         0.000439   2.582       5.00E‐03   2.34 (1.27--4.31)   0.0049
  212816_s\_at    Hs.84152.2      CBS           4.55         0.000561   2.658       1.00E‐03   2.06 (1.14--3.74)   0.0146
  205394_at       g4502802        CHEK1         4.6          0.000004   4.147       2.43E‐07   2.04 (1.13--3.66)   0.015
  221436_s\_at    g13876383       CDCA3         4.65         0.001047   4.847       1.30E‐09   2.09 (1.15--3.77)   0.0128
  207109_at       g7657408        POU2F3        4.66         0.024312   1.741       4.43E‐04   2.81 (1.53--5.18)   0.0005
  202219_at       g5032096        SLC6A8        4.68         0.000195   1.94        1.76E‐07   2.17 (1.18--4)      0.0108
  217025_s\_at    Hs.89434.1      DBN1          4.69         0.007175   2.141       1.84E‐06   2.11 (1.13--3.93)   0.0163
  202338_at       g4507518        TK1           4.73         0.00005    4.968       1.55E‐08   2.07 (1.13--3.77)   0.0156
  222251_s\_at    Hs.28906.1      GMEB2         4.81         0.004936   1.339       3.27E‐04   5.5 (2.57--11.76)   0
  210697_at       g4454677        ZNF257        4.82         0.001284   1.673       1.66E‐05   2.06 (1.15--3.7)    0.0135
  214339_s\_at    Hs.86575.2      MAP4K1        4.87         0.000074   1.866       1.13E‐05   2.07 (1.13--3.79)   0.0154
  203022_at       g5454009        RNASEH2A      4.94         0.000147   2.785       1.11E‐06   2.06 (1.13--3.76)   0.016
  206280_at       g4826670        CDH18         4.96         0.006096   1.396       0.004      2.05 (1.14--3.7)    0.0143
  211343_s\_at    g180828         COL13A1       5            0.000822   1.318       3.17E‐04   2.05 (1.13--3.75)   0.0165
  206513_at       g4757733        AIM2          5.02         0.007612   1.547       6.09E‐04   2.73 (1.46--5.11)   0.0011
  204994_at       g11342663       MX2           5.03         0.001647   3.916       3.32E‐04   2.2 (1.19--4.06)    0.0098
  205163_at       g7019426        MYLPF         5.04         0.000789   1.397       4.94E‐06   1.97 (1.1--3.54)    0.0201
  218726_at       g8922180        HJURP         5.07         0.010918   5.547       2.20E‐09   1.95 (1.08--3.5)    0.023
  239219_at       Hs.221197.0     AURKB         5.1          0.001028   2.818       2.34E‐05   2.22 (1.04--4.76)   0.0353
  202575_at       g6382069        CRABP2        5.27         0.000004   3.216       9.08E‐05   2.08 (1.16--3.74)   0.0124
  35160_at        4870487_RC      LDB1          5.29         0.00032    1.5         1.00E‐03   2.35 (1.27--4.32)   0.0048
  212556_at       Hs.239784.0     SCRIB         5.31         5.24E‐07   2.578       8.65E‐07   2 (1.1--3.65)       0.021
  203439_s\_at    g12653744       STC2          5.31         0.001003   2.509       1.53E‐06   1.85 (1.03--3.35)   0.0379
  234040_at       Hs.287543.0     HELLS         5.35         0.004925   2.352       3.86E‐05   2.39 (1.11--5.11)   0.0209
  221125_s\_at    g7657250        KCNMB3        5.47         0.000016   1.637       2.06E‐06   2.03 (1.11--3.71)   0.0183
  205569_at       g7657660        LAMP3         5.48         0.040774   3.979       3.15E‐04   3.56 (1.85--6.85)   0.0001
  213520_at       Hs.31442.0      RECQL4        5.48         0.00012    1.358       0.002      2.61 (1.4--4.87)    0.0018
  205034_at       g4757931        CCNE2         5.49         0.00002    1.344       2.00E‐03   2.29 (1.27--4.11)   0.0046
  222037_at       Hs.154443.1     MCM4          5.52         0.013214   4.726       8.00E‐08   2.9 (1.55--5.41)    0.0005
  218494_s\_at    g13236503       SLC2A4RG      5.64         0.000878   2.118       5.86E‐06   2.48 (1.33--4.62)   0.0031
  212235_at       Hs.301685.0     PLXND1        5.64         0.000117   1.496       4.67E‐04   2.05 (1.13--3.71)   0.0152
  218296_x\_at    g8922469        MSTO1         5.72         0.000026   1.381       0.018      1.83 (1--3.33)      0.0458
  218009_s\_at    g4506038        PRC1          5.74         9.19E‐07   7.214       5.32E‐08   2.85 (1.53--5.32)   0.0006
  209680_s\_at    g12653842       KIFC1         5.78         0.000129   3.845       3.64E‐08   2.33 (1.28--4.24)   0.0046
  202954_at       g5902145        UBE2C         5.81         2.13E‐08   10.184      2.24E‐07   3.03 (1.62--5.66)   0.0003
  205240_at       g9558734        GPSM2         6.01         0.000545   3.965       2.97E‐08   1.81 (1.01--3.25)   0.0435
  209262_s\_at    g12803666       NR2F6         6.05         2.41E‐07   1.61        2.18E‐05   2.26 (1.23--4.17)   0.0071
  203632_s\_at    g7706450        GPRC5B        6.12         0.000022   1.672       0.004      2.22 (1.21--4.04)   0.0078
  207165_at       g7108350        HMMR          6.14         0.000011   3.819       1.48E‐10   2.35 (1.3--4.25)    0.0037
  205046_at       g4502780        CENPE         6.16         0.00057    2.711       1.59E‐07   2.55 (1.36--4.75)   0.0024
  208394_x\_at    g13259505       ESM1          6.2          0.000021   1.496       0.009      2.05 (1.13--3.71)   0.0152
  216237_s\_at    Hs.77171.1      MCM5          6.22         0.001843   1.795       7.33E‐05   2.33 (1.25--4.34)   0.0063
  205449_at       g9558738        SAC3D1        6.31         0.000029   1.891       3.53E‐05   2.19 (1.2--4)       0.0086
  203099_s\_at    g4558755        CDYL          6.33         0.000004   1.889       4.26E‐05   2.1 (1.15--3.83)    0.013
  210983_s\_at    g12751125       MCM7          6.48         0.008102   3.523       2.31E‐07   2.23 (1.21--4.1)    0.0084
  210052_s\_at    g6073830        TPX2          6.5          2.90E‐08   13.887      1.65E‐07   2.55 (1.38--4.69)   0.0019
  225846_at       Hs.24743.1      ESRP1         6.53         0.000005   2.135       2.68E‐04   2.3 (1.04--5.06)    0.0335
  218308_at       g5454101        TACC3         6.54         0.000462   4.047       9.61E‐06   4.1 (2.04--8.24)    0
  239570_at       Hs.144137.0     RAB1A         6.76         0.000581   1.31        3.07E‐04   2.48 (1.1--5.6)     0.0242
  203358_s\_at    g4758323        EZH2          6.84         0.000002   6.584       1.44E‐06   3.63 (1.93--6.8)    0
  203806_s\_at    g4503654        FANCA         6.87         0.00001    1.793       7.55E‐05   2.69 (1.42--5.08)   0.0016
  219502_at       g8922721        NEIL3         6.91         0.000004   1.519       1.08E‐05   2.36 (1.3--4.28)    0.0035
  208079_s\_at    g4507278        AURKA         7            3.64E‐08   6.504       6.53E‐08   2.95 (1.6--5.45)    0.0003
  204709_s\_at    g13699831       KIF23         7            0.000061   4.68        2.17E‐06   2.7 (1.48--4.95)    0.0008
  203755_at       g5729749        BUB1B         7.09         6.83E‐10   8.04        2.56E‐07   2.86 (1.55--5.29)   0.0004
  222039_at       Hs.274448.1     KIF18B        7.2          6.26E‐09   2.135       4.91E‐06   2.4 (1.31--4.37)    0.0032
  204822_at       g4507718        TTK           7.21         7.51E‐07   15.153      2.06E‐09   2.52 (1.38--4.61)   0.0019
  212023_s\_at    Hs.80976.1      MKI67         7.25         1.04E‐07   4.023       5.17E‐10   1.94 (1.07--3.51)   0.0256
  204170_s\_at    g4502858        CKS2          7.39         6.82E‐08   5.956       3.85E‐05   2.06 (1.14--3.73)   0.0147
  207183_at       g5453665        GPR19         7.43         0.000063   2.901       8.95E‐09   3.07 (1.64--5.72)   0.0002
  207828_s\_at    g4885132        CENPF         7.52         0.000002   3.811       1.75E‐06   2.64 (1.43--4.87)   0.0013
  206157_at       g4506332        PTX3          7.56         0.000006   2.79        0.004      2.93 (1.6--5.37)    0.0003
  218039_at       g7705950        NUSAP1        7.63         5.89E‐09   9.731       7.45E‐07   2.08 (1.16--3.75)   0.0123
  203554_x\_at    g11038651       PTTG1         7.68         0.000002   5.99        1.80E‐05   3.34 (1.76--6.34)   0.0001
  209891_at       g9963834        SPC25         7.73         0.000027   2.928       9.73E‐24   2.45 (1.34--4.47)   0.0026
  221520_s\_at    g12804484       CDCA8         7.78         0.000076   3.705       5.44E‐07   2.63 (1.41--4.91)   0.0016
  218755_at       g5032012        KIF20A        7.9          1.87E‐08   9.021       9.21E‐08   2.56 (1.37--4.78)   0.0021
  201761_at       g13699869       MTHFD2        7.92         0.000004   3.82        1.20E‐04   2.68 (1.45--4.94)   0.001
  204649_at       g4885624        TROAP         7.95         0.000014   3.096       5.11E‐08   2.83 (1.49--5.35)   0.0008
  209408_at       g1695881        KIF2C         8.01         2.31E‐08   2.834       6.75E‐11   2.43 (1.33--4.44)   0.003
  201663_s\_at    g4885112        SMC4          8.12         0.008518   7.44        9.32E‐09   2.55 (1.38--4.71)   0.0019
  218542_at       g8922501        CEP55         8.28         0.000158   8.075       1.50E‐08   1.89 (1.05--3.4)    0.0304
  222958_s\_at    Hs.133260.0     DEPDC1        8.47         0.000182   3.833       2.12E‐07   2.61 (1.19--5.7)    0.0127
  222008_at       Hs.154850.0     COL9A1        8.48         0.000545   1.946       2.30E‐16   1.93 (1.08--3.47)   0.0249
  210512_s\_at    g3719220        VEGFA         8.51         6.97E‐09   2.741       1.17E‐07   3.37 (1.75--6.48)   0.0001
  205733_at       g4557364        BLM           8.53         0.000002   2.88        3.59E‐06   1.99 (1.1--3.59)    0.0205
  236641_at       Hs.116649.0     KIF14         8.88         0.000311   3.139       5.27E‐06   2.28 (1.01--5.13)   0.0414
  204962_s\_at    g4585861        CENPA         8.9          0.000014   11.775      2.63E‐09   2.48 (1.35--4.57)   0.0026
  202705_at       g10938017       CCNB2         9.15         1.13E‐07   10.154      1.59E‐06   1.87 (1.04--3.37)   0.0329
  218585_s\_at    g7705575        DTL           9.2          2.49E‐10   6.089       1.58E‐07   1.89 (1.06--3.38)   0.0289
  38158_at        4852842_RC      ESPL1         9.2          8.96E‐09   4.341       6.11E‐07   3.19 (1.69--6.04)   0.0002
  213523_at       Hs.9700.0       CCNE1         9.36         2.03E‐07   7.062       8.28E‐09   1.84 (1.02--3.33)   0.0407
  222946_s\_at    g12652906       AUNIP         9.41         0.00175    2.956       7.47E‐08   2.11 (0.99--4.52)   0.0485
  213075_at       Hs.94795.0      OLFML2A       9.44         0.000481   1.423       3.00E‐03   1.86 (1.04--3.34)   0.0348
  204825_at       g7661973        MELK          9.59         0.000007   10.6        2.98E‐07   1.95 (1.08--3.5)    0.0233
  212563_at       Hs.30736.0      BOP1          9.61         0.000165   1.669       3.35E‐06   2.03 (1.11--3.69)   0.0186
  204026_s\_at    g6857828        ZWINT         9.92         1.65E‐09   7.001       1.71E‐05   2.05 (1.14--3.7)    0.015
  202580_x\_at    g11386144       FOXM1         10.06        0.000022   5.982       8.64E‐09   3.03 (1.6--5.73)    0.0003
  205694_at       g4507756        TYRP1         10.15        0.000772   1.624       2.09E‐34   1.79 (1--3.23)      0.0486
  204584_at       Hs.1757.0       L1CAM         10.27        0.000008   3.985       7.02E‐15   3.02 (1.63--5.58)   0.0002
  218662_s\_at    g11641252       NCAPG         10.35        4.18E‐08   3.207       2.13E‐10   3.28 (1.76--6.14)   0.0001
  204695_at       Hs.1634.0       CDC25A        10.39        0.000002   2.633       2.49E‐05   2.39 (1.31--4.34)   0.0033
  212807_s\_at    Hs.281706.1     SORT1         10.54        4.63E‐07   1.977       9.60E‐06   2.05 (1.12--3.75)   0.0172
  202094_at       Hs.1578.0       BIRC5         10.82        0.000018   4.83        2.20E‐10   2.85 (1.53--5.31)   0.0006
  204558_at       g4506396        RAD54L        11.24        0.000856   2.09        6.38E‐06   2.85 (1.53--5.32)   0.0006
  218355_at       g7305204        KIF4A         11.53        5.42E‐08   2.359       1.00E‐03   2.82 (1.51--5.27)   0.0007
  219650_at       g8923111        ERCC6L        12.29        6.30E‐07   2.245       8.13E‐06   2.24 (1.24--4.04)   0.0063
  204437_s\_at    g9257206        FOLR1         12.72        0.000017   1.696       2.00E‐03   2.05 (1.13--3.7)    0.0155
  203418_at       g4502612        CCNA2         13.14        0.00196    4.795       2.28E‐07   1.82 (1.02--3.26)   0.0403
  205242_at       g5453576        CXCL13        16.29        0.0001     2.091       2.94E‐08   1.83 (1.02--3.28)   0.0411
  205572_at       g4557314        ANGPT2        19.81        0.000006   1.312       0.029      2.02 (1.12--3.63)   0.0164
  212949_at       Hs.1192.0       NCAPH         19.94        7.17E‐07   2.497       1.51E‐06   3.06 (1.62--5.78)   0.0003
  206772_at       g4826953        PTH2R         21.94        0.000027   5.579       8.58E‐10   3.14 (1.66--5.97)   0.0002
  222962_s\_at    g11527601       MCM10         29.44        6.72E‐09   2.718       1.28E‐07   2.33 (1.06--5.1)    0.0296
  207039_at       g4502748        CDKN2A        45.1         0.000022   6.481       5.60E‐14   2.01 (1.11--3.63)   0.0186
  206373_at       g4507970        ZIC1          99.77        2.13E‐08   3.712       8.24E‐07   2.19 (1.22--3.93)   0.0073
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Functional gene signatures associated with poor outcome {#cam41406-sec-0010}
-------------------------------------------------------

Functional annotation of the identified genes demonstrated several altered functions (Fig. [1](#cam41406-fig-0001){ref-type="fig"}A and B). By selecting those more represented (with a more than 20% of total genes expression), we identified cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular (EC) stimuli, and transcription regulation. Table [S1](#cam41406-sup-0002){ref-type="supplementary-material"} provides detailed information of all functions and genes included within each function.

Using the KM Plotter online tool, we explored the association with clinical outcome of genes within each function. We did so to observe the role of each group with clinical prognosis. Genes within the cell cycle and cell division were associated with detrimental PFS and OS (PFS: HR = 4.07 (95% CI 1.66--9.98), *P* = 0.00086 and OS: HR = 3.33 (95% CI 0.94--11.81), *P* = 0.048 for cell cycle and PFS: HR = 3.58 (95% CI 1.46--8.78), *P* = 0.0029 and OS HR =  3.52 (95% CI 0.99--12.46), *P* = 0.038, for cell division) (Fig. [2](#cam41406-fig-0002){ref-type="fig"}). Results in the same range were observed for signal transduction/protein modification (PFS HR = 3.73 (95% CI 1.52--9.14), *P* = 0.002 and OS HR =  3.33 (95% CI 0.94--11.81), *P* = 0.048) and for transcription regulation PFS data (PFS: HR = 3.69 (95% CI 1.51--9.03), *P* = 0.0022). Interestingly, a poorer outcome for OS was found for this latter group (OS: HR = 12.55 (95% CI 1.65--95.48), *P* = 0.0017) (Fig. [3](#cam41406-fig-0003){ref-type="fig"}). Finally, the group of genes within the cellular response to EC stimuli function showed the worse outcome for both PFS and OS (PFS: HR = 6.37 (95% CI 2.22--18.28), *P* = 7.7e‐05 and OS: HR = 13.25 (95% CI 1.74--100.79), (Fig. [3](#cam41406-fig-0003){ref-type="fig"}).

![Association with progression‐free survival (PFS) and overall survival (OS) in stage I and II ovarian cancer of gene sets included in the cell cycle and cell division function.](CAM4-7-1896-g002){#cam41406-fig-0002}

![Association with progression‐free survival (PFS) and overall survival (OS) in stage I and II ovarian cancer of gene sets included in the cellular response to extracellular (EC) stimuli, signal transduction/protein modification and transcription regulation function.](CAM4-7-1896-g003){#cam41406-fig-0003}

Druggable opportunities within the identified functions {#cam41406-sec-0011}
-------------------------------------------------------

The description of functional signatures has the advantage of identifying relevant molecular alterations that have a potential oncogenic role in this disease, and therefore are susceptible to be inhibited. To get insights into potential therapies for those patients harboring these signatures, we used the drug gene interaction database available in Genecards and confirmed by other sources as described in [Material and Methods](#cam41406-sec-0002){ref-type="sec"}. We therefore selected 26 genes that could potentially be inhibited pharmacologically (Table [S2](#cam41406-sup-0003){ref-type="supplementary-material"}). We next used the proteins coded by these genes to build a protein--protein interaction network. We found 223 interactions (edges) linking 26 proteins (nodes). As expected, the clustering coefficient in this druggable network was high (0.85), confirming that most of the proteins act as a functional unit. We identified three different functional clusters with special affinity: Cell cycle (*n *= 19 genes), DNA damage (*n *= 4 genes), and angiogenesis (*n *= 3 genes) (Fig. [4](#cam41406-fig-0004){ref-type="fig"}A). Of note, DNA damage was included as part of the cellular response to EC stimuli in our initial functional annotation, and angiogenesis was one of the functions identified in the functional annotation studies, although was less represented (Table [S1](#cam41406-sup-0002){ref-type="supplementary-material"}). These results suggest an important role of this in the druggable PPI. Next, based on the number of interactions, we selected the hub proteins of the interactome, defined as those with a higher number of interactions than the average (Edges ≥17.2; *n *= 18) (Fig. [4](#cam41406-fig-0004){ref-type="fig"}B).

![Protein--protein interaction (PPI) map of the 26 potential druggable targets. (A) Potentially druggable targets were used to construct a PPI network using the online tool STRING. Blue nodes represent proteins involved in cell cycle. Red and green nodes represent proteins associated with DNA damage and angiogenesis, respectively. The nodes indicate proteins coded by the identified druggable targets and edges indicate the number of interactions. The number of average interactions per node is represented by the node degree. The clustering coefficient indicates the average node density of the map. (B) List of hub proteins according the number of interactions (edges) in the druggable PPI network.](CAM4-7-1896-g004){#cam41406-fig-0004}

Some of the genes identified here have been described previously in ovarian cancer as deregulated, including *AURKA, AURKB, CDK1, BIRC5,* and *CHEK1* among others [6](#cam41406-bib-0006){ref-type="ref"}. Of note, the histone‐lysine N‐methyltransferase EZH2 is a novel epigenetic target not previously described, and the ubiquitin‐conjugating enzyme E2C (UBE2C), which belongs to the ubiquitin ligase family of enzymes is also a potentially druggable protein with limited evaluation in ovarian cancer. Interestingly, these two genes strongly associate with worse prognosis for OS (Table [S3](#cam41406-sup-0004){ref-type="supplementary-material"})

Molecular alterations in the identified signatures {#cam41406-sec-0012}
--------------------------------------------------

To complete our study, we used the cancer genomics database (cBioportal [7](#cam41406-bib-0007){ref-type="ref"}) to obtain information about copy number alterations or mutations of the identified druggable genes. Most of genes that code for the identified druggable hubs were found to be amplified in ovarian cancer (Table [2](#cam41406-tbl-0002){ref-type="table-wrap"}). Of note, the new potential targets *EZH2* and *UBE2C* were amplified in around 10% and 6% of ovarian cancers, respectively. Deletions and mutations were present at a very low frequency. Amplifications of other genes such as *RAD54L, AURKA, KIF2C,* or *BIRC5* were also observed.

###### 

Molecular alterations of the identified hub proteins

  311 Ovarian serous cystadenocarcinoma samples                    
  ----------------------------------------------- -------- ------- -------
  **EZH2**                                        10.30%   0.30%   --
  RAD54L                                          9.00%    --      0.60%
  AURKA                                           8.70%    --      --
  KIF2C                                           6.40%    --      0.30%
  BIRC5                                           6.10%    0.60%   --
  **UBE2C**                                       5.80%    --      --
  BLM                                             5.50%    0.30%   1.30%
  CHEK1                                           3.90%    0.60%   --
  MKI67                                           3.50%    1.00%   1.30%
  MCM7                                            3.20%    --      --
  KIF4A                                           1.90%    0.30%   0.60%
  CDK1                                            1.90%    --      0.60%
  TTK                                             1.60%    0.30%   0.60%
  MELK                                            1.30%    --      0.60%
  KIF15                                           1.00%    0.30%   0.30%
  CENPE                                           0.60%    1.30%   0.60%
  AURKB                                           0.60%    0.60%   --
  KIF11                                           0.60%    0.30%   --
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Discussion {#cam41406-sec-0013}
==========

In the present article, we describe functional gene signatures and PPI networks associated with adverse outcome in early stage ovarian cancer. These signatures and interacting protein networks provide information about druggable opportunities that could be validated preclinically.

As ovarian cancer is an incurable disease, the identification of oncogenic functions and protein interacting networks associated with detrimental outcome is expected to improve the therapeutic landscape of this disease. In early stage ovarian cancer, the identification of patients with worse outcome is even more relevant as it may help in the selection of patients for additional adjuvant therapy, and even guide the evaluation of novel therapies.

In our study, we have identified five functions linked with detrimental PFS and OS in early stage ovarian cancer. Within cell cycle and cell division, we found genes such as *AURKA, AURKB, CDK1, BIRC5,* and *CHEK1* that are associated with control of mitosis and cell cycle regulation [8](#cam41406-bib-0008){ref-type="ref"}. Of note, some of these genes have been reported previously to be linked with detrimental outcome [6](#cam41406-bib-0006){ref-type="ref"}. Inhibitors against proteins coded by these genes, such as AURKA and B or CHEK1, are currently in clinical development, so our findings provide support for the specific development of those agents in ovarian cancer.

An interesting finding was the identification of protein modifications and transcription regulation as upregulated functions. Protein modification and degradation is a vulnerability of tumor cells as has been demonstrated by the clinical activity of proteasome inhibitors in some hematological malignancies [9](#cam41406-bib-0009){ref-type="ref"}, [10](#cam41406-bib-0010){ref-type="ref"}. Ubiquitination is a necessary pathway to target proteins for degradation [11](#cam41406-bib-0011){ref-type="ref"}. The ubiquitin‐conjugating enzyme E2C is required for the destruction of mitotic cyclins and for cell cycle progression [12](#cam41406-bib-0012){ref-type="ref"}. UBE2C has been found to be overexpressed in esophageal squamous cell carcinoma playing a role in cancer progression [13](#cam41406-bib-0013){ref-type="ref"}, [14](#cam41406-bib-0014){ref-type="ref"}, as well as, in other tumor types such as nonsmall cell lung cancer [15](#cam41406-bib-0015){ref-type="ref"}. However, there are no published data regarding the role of this protein in ovarian cancer. As this family of proteins can be inhibited pharmacologically [11](#cam41406-bib-0011){ref-type="ref"}, the study of such agents in ovarian cancer is warranted.

Other relevant findings include the identification of EZH2 as upregulated and involved in the PPI network. EZH2 has been associated with epithelial to mesenchymal transition in ovarian cancers [16](#cam41406-bib-0016){ref-type="ref"}. Of note, EZH2 inhibitors seem to be particularly active in malignant rhabdoid tumors, which are deficient in the Switch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complexes INI1 (SMARCB1). Of interest, a subgroup of ovarian tumors has a similar phenotype and has shown responses to inhibitors of this complex [17](#cam41406-bib-0017){ref-type="ref"}. In our study, we observe that EZH2 is a relevant component of the PPI network therefore confirming a potentially druggable vulnerability. Of note, drugs such as tazemetostat, a potent and selective EZH2 inhibitor is currently in phase II testing [18](#cam41406-bib-0018){ref-type="ref"}. Other molecular alteration includes *RAD54L* that is amplified in 9% of patients. The protein associated by this gene is involved in the homologous recombination repair of DNA double‐strand breaks [19](#cam41406-bib-0019){ref-type="ref"}. Finally, genes such as *KIF2C* or *AURKA* are involved in mitotic formation and chromosome segregation [20](#cam41406-bib-0020){ref-type="ref"}.

Our analysis highlights several druggable functions in early stage ovarian cancer for which new agents are currently in preclinical or clinical evaluation. However, we should acknowledge that our study has some limitations. This is an *in silico* analysis that need confirmatory studies using human samples. In addition, functional assessment has the limitation for the redundancy of functions, as many genes can be classified in many different annotations. Finally, there are limitations for the existed software that help identifying druggable opportunities mainly for redundancy.

In conclusion, we have identified biological functions and PPI networks that are prognostic in early stage ovarian cancer and may guide future drug development (Fig. [5](#cam41406-fig-0005){ref-type="fig"}). Some of the identified genes such as *EZH2* or *UBE2C* have not been described previously in ovarian cancer but are amplified, linked with detrimental prognosis and potentially druggable, and warrant preclinical and clinical assessment.

![Study graphical abstract.](CAM4-7-1896-g005){#cam41406-fig-0005}
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**Table S3.** Association with progression free survival (PFS) and overall survival (OS) of the identified hub proteins.
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**Figure S1.** Protein‐protein interaction network of the 130 deregulated genes associated with detrimental prognosis.
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